RxSight, Inc. (NASDAQ:RXST) Shares Purchased by Algert Global LLC

Algert Global LLC increased its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 30.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 83,530 shares of the company's stock after purchasing an additional 19,382 shares during the period. Algert Global LLC owned approximately 0.21% of RxSight worth $2,872,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in RXST. Barclays PLC lifted its holdings in RxSight by 389.8% during the 3rd quarter. Barclays PLC now owns 58,786 shares of the company's stock valued at $2,906,000 after buying an additional 46,783 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in RxSight by 4.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,510 shares of the company's stock valued at $9,516,000 after buying an additional 7,494 shares in the last quarter. Paragon Advisors LLC lifted its holdings in RxSight by 20.5% during the 4th quarter. Paragon Advisors LLC now owns 37,822 shares of the company's stock valued at $1,300,000 after buying an additional 6,423 shares in the last quarter. Harbor Investment Advisory LLC bought a new stake in RxSight during the 4th quarter valued at about $52,000. Finally, KBC Group NV raised its holdings in shares of RxSight by 71.0% in the 4th quarter. KBC Group NV now owns 2,107 shares of the company's stock valued at $72,000 after purchasing an additional 875 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Price Performance

NASDAQ:RXST traded up $0.82 during trading hours on Monday, hitting $13.88. 1,332,599 shares of the company were exchanged, compared to its average volume of 659,752. The company's 50 day moving average price is $19.28 and its 200-day moving average price is $31.26. The stock has a market capitalization of $563.88 million, a price-to-earnings ratio of -16.74 and a beta of 1.32. RxSight, Inc. has a 52-week low of $13.03 and a 52-week high of $64.50.

RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $37.90 million for the quarter, compared to the consensus estimate of $38.74 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The business's revenue for the quarter was up 28.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.25) EPS. On average, equities analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current year.

Insider Activity

In other news, Director Tamara Fountain sold 7,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now directly owns 24,793 shares of the company's stock, valued at $637,428.03. This represents a 22.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.36% of the company's stock.

Wall Street Analysts Forecast Growth

RXST has been the subject of several recent research reports. Piper Sandler initiated coverage on shares of RxSight in a report on Tuesday, April 15th. They issued a "neutral" rating and a $18.00 price target for the company. Needham & Company LLC restated a "buy" rating and issued a $43.00 price target on shares of RxSight in a report on Thursday, April 3rd. UBS Group downgraded shares of RxSight from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $45.00 to $16.00 in a research report on Wednesday, April 9th. Wells Fargo & Company cut their price objective on shares of RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 3rd. Finally, Bank of America reaffirmed an "underperform" rating and issued a $22.00 price objective (down previously from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, RxSight presently has a consensus rating of "Hold" and a consensus price target of $37.60.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.